ST. HELIER, Jersey (AP) _ NovoCure Ltd. (NVCR) on Thursday reported a third-quarter loss of $13.1 million, after reporting a profit in the same period a year earlier.

The St. Helier, Jersey-based company said it had a loss of 13 cents per share.

The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 6 cents per share.

The oncology drug developer posted revenue of $133.6 million in the period, which also missed Street forecasts. Five analysts surveyed by Zacks expected $142.8 million.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NVCR at https://www.zacks.com/ap/NVCR

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News